Free Trial

Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California logo
$1.80 +0.03 (+1.69%)
(As of 11/22/2024 ET)

PACB vs. QTRX, FLDM, HBIO, BLI, AXDX, TMO, A, MTD, WAT, and ILMN

Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Berkeley Lights (BLI), Accelerate Diagnostics (AXDX), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Illumina (ILMN).

Pacific Biosciences of California vs.

Quanterix (NASDAQ:QTRX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.

Quanterix currently has a consensus price target of $23.25, indicating a potential upside of 97.87%. Pacific Biosciences of California has a consensus price target of $3.63, indicating a potential upside of 101.39%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quanterix
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Pacific Biosciences of California
0 Sell rating(s)
8 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.47

Quanterix has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Quanterix has a net margin of -30.71% compared to Pacific Biosciences of California's net margin of -227.69%. Quanterix's return on equity of -11.52% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Quanterix-30.71% -11.52% -9.47%
Pacific Biosciences of California -227.69%-42.71%-15.38%

Pacific Biosciences of California received 181 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 66.86% of users gave Pacific Biosciences of California an outperform vote while only 61.56% of users gave Quanterix an outperform vote.

CompanyUnderperformOutperform
QuanterixOutperform Votes
269
61.56%
Underperform Votes
168
38.44%
Pacific Biosciences of CaliforniaOutperform Votes
450
66.86%
Underperform Votes
223
33.14%

Quanterix has higher earnings, but lower revenue than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quanterix$122.37M3.69-$32.33M-$1.05-11.19
Pacific Biosciences of California$200.52M2.46-$306.73M-$1.46-1.23

In the previous week, Quanterix had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 9 mentions for Quanterix and 8 mentions for Pacific Biosciences of California. Quanterix's average media sentiment score of 0.03 beat Pacific Biosciences of California's score of -0.04 indicating that Quanterix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quanterix
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pacific Biosciences of California
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

86.5% of Quanterix shares are owned by institutional investors. 6.9% of Quanterix shares are owned by company insiders. Comparatively, 2.4% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Quanterix beats Pacific Biosciences of California on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PACB vs. The Competition

MetricPacific Biosciences of CaliforniaAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$492.95M$5.46B$5.21B$8.85B
Dividend YieldN/A0.44%5.53%4.08%
P/E Ratio-1.2312.3982.8815.55
Price / Sales2.464.061,246.7687.28
Price / CashN/A42.9440.9136.92
Price / Book1.092.507.206.55
Net Income-$306.73M$515,312.50$119.63M$226.22M
7 Day Performance12.85%1.55%2.12%3.77%
1 Month Performance2.86%-2.61%-2.43%4.64%
1 Year Performance-78.47%-16.01%34.53%29.21%

Pacific Biosciences of California Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PACB
Pacific Biosciences of California
1.365 of 5 stars
$1.80
+1.7%
$3.63
+101.4%
-78.5%$492.95M$200.52M-1.23730
QTRX
Quanterix
2.4117 of 5 stars
$11.75
+6.6%
$23.25
+97.9%
-51.4%$450.97M$122.37M-11.23460News Coverage
FLDM
Fluidigm
N/AN/AN/AN/A$283.76M$130.58M-4.76615Analyst Forecast
HBIO
Harvard Bioscience
1.5607 of 5 stars
$2.16
flat
N/A-47.8%$94.21M$97.73M-6.55490Positive News
High Trading Volume
BLI
Berkeley Lights
0.7847 of 5 stars
N/AN/AN/A$72.04M$78.60M-0.70293
AXDX
Accelerate Diagnostics
2.4584 of 5 stars
$1.67
-1.8%
$1.00
-40.1%
-64.7%$41.82M$12.06M-0.58134Negative News
TMO
Thermo Fisher Scientific
4.9919 of 5 stars
$515.26
+0.5%
$649.33
+26.0%
+5.3%$197.09B$42.86B32.30122,000Buyback Announcement
Positive News
A
Agilent Technologies
4.2492 of 5 stars
$131.94
+2.6%
$144.36
+9.4%
+7.9%$37.91B$6.83B27.3718,100Upcoming Earnings
Dividend Increase
News Coverage
MTD
Mettler-Toledo International
3.6726 of 5 stars
$1,195.00
+2.4%
$1,338.75
+12.0%
+12.9%$25.21B$3.79B32.2217,300Positive News
WAT
Waters
4.1844 of 5 stars
$368.00
+2.9%
$365.85
-0.6%
+35.2%$21.85B$2.96B35.117,900
ILMN
Illumina
4.5414 of 5 stars
$137.09
+4.1%
$164.00
+19.6%
+43.4%$21.74B$4.50B-13.769,300

Related Companies and Tools


This page (NASDAQ:PACB) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners